Follow-Up Visits After Breast Cancer: What Is Checked at Each Stage of Recovery

The last radiation session ends with a small ceremony in many treatment centers: a bell, a certificate, applause from the nurses. Then the patient walks out into the parking lot and realizes nobody has told her what Tuesday looks like. For months, life ran on appointment cards. Now the calendar is blank, and the blankness feels less like freedom than like standing on a ledge.

That gap is exactly what a breast cancer follow up schedule is designed to fill. It is not a random string of check-ins. Each visit in the first year has a different job from a visit in year four, and understanding those jobs turns anxious waiting into something closer to a plan.

This explainer walks through what is actually examined at each stage, why some tests are deliberately left out, and which changes deserve a phone call before the next scheduled date. The details of your own plan belong to your oncology team; what follows is the map they are working from.

What is breast cancer follow-up actually for?

Follow-up care serves three purposes that pull in slightly different directions. The first is to catch a recurrence, meaning cancer that has come back in the treated breast, the chest wall, the nearby lymph nodes, or elsewhere in the body, early enough to treat it well. The second is to manage the aftermath of treatment itself: a stiff shoulder, a swollen arm, thinning bones, hot flashes, a heart working a little harder than it used to. The third, easy to overlook, is to help a person live the years that treatment made possible.

The National Cancer Institute describes follow-up as regular medical checkups after treatment that include a review of health history, a physical exam, and tests chosen for the specific cancer and treatment received. That word chosen matters. Breast cancer surveillance is not a matter of scanning everything every time. Decades of trial data showed that intensive scanning of people without symptoms did not help them live longer, so guidelines lean on the exam, the conversation, and one imaging test: the mammogram.

A useful way to picture it is a set of dials. In the first year the dial points hard toward healing and side effects. Over years two through five it swings toward recurrence detection and the long tail of hormone therapy. Beyond five years it settles on general health, because a person who has had breast cancer still has a heart, bones, and a second breast that need ordinary care.

Every visit is also a chance to say the thing you were unsure was worth mentioning. Oncology nurses will tell you the most important information often comes out in the last two minutes, when a patient says, almost as an afterthought, that a spot on her rib has ached for a month.

What does a typical breast cancer follow up schedule look like?

Most schedules follow a tapering pattern. Professional oncology guidelines in the United States commonly describe a history and physical examination every three to six months for the first three years after primary treatment, every six to twelve months in years four and five, and once a year after that. The NHS describes regular check-ups after treatment and a yearly mammogram for five years, after which people move into the routine screening program appropriate for their age. Some centers keep patients under specialist review longer; others hand over to primary care sooner. Neither approach is wrong, and the exact spacing is a decision for your treating team.

The table below summarizes what is commonly reviewed at each stage. Think of it as a framework rather than a contract.

Stage	Typical spacing	Main focus of the visit
First year	Every 3–6 months	Healing of surgery and radiation, arm function, starting hormone therapy, heart monitoring if on HER2-targeted drugs
Years 2–3	Every 3–6 months	Clinical exam for recurrence, hormone therapy side effects, bone density if indicated, annual mammogram
Years 4–5	Every 6–12 months	Same checks, plus planning for the end or extension of hormone therapy
Beyond year 5	Yearly	Annual mammogram, general health, late effects, possible transfer to primary care

Notice what is not in the table: no routine CT, bone scan, PET scan, or blood tumor markers. Their absence is deliberate and is explained in a later section. Notice also that the spacing tightens where the risk of recurrence is statistically highest, in the first few years for many tumor types, and loosens as time passes.

One caution about the word typical. A person with a hormone receptor–positive tumor, a person who had a double mastectomy, and a person with an inherited gene variant will each get a different version of this schedule. The rest of this article explains why.

What happens at a breast cancer follow up appointment?

The visit usually starts before the doctor walks in. A nurse records weight and blood pressure, and you may be asked how you have been feeling since the last visit, whether any new symptoms have appeared, and how you are managing any medication. If your clinic uses a symptom questionnaire, this is when you fill it in. Answer it honestly; it steers the conversation.

The physical examination is the core of the appointment. The clinician looks at and feels the treated breast or the mastectomy scar, the skin of the chest wall, and the area under the arm and above the collarbone where lymph nodes sit. The other breast is examined too. Both arms are compared for swelling, and the shoulder is checked for range of motion. Many clinicians also press gently along the spine and ribs and listen to the chest, because bones and lungs are common sites of distant recurrence and a quick check costs nothing.

Then comes the conversation, which is longer than most people expect. Expect questions about hot flashes, sleep, joint aches, vaginal dryness, mood, sexual health, and whether you are taking hormone therapy as prescribed. These are not small talk. Mayo Clinic notes that side effects are a leading reason people stop endocrine therapy early, and a follow-up visit is where a clinician can adjust how those effects are managed.

Tests are ordered selectively. An annual mammogram is arranged if you have remaining breast tissue. A bone density scan may be scheduled if you take an aromatase inhibitor. Blood tests are generally only requested to monitor a specific medication or investigate a specific symptom.

The appointment ends with a plan: when the next visit is, what to watch for in between, and who to call. Writing that down, or asking for it in writing, saves a lot of second-guessing later.

The first weeks after surgery: what is checked and why

The first follow-up usually comes within a couple of weeks of a lumpectomy or mastectomy, and it is a surgical visit rather than an oncology one. Its job is straightforward: make sure the body is healing and give you the pathology results.

The surgeon inspects the incision for redness, warmth, gaping, or discharge, all of which can signal infection. If a drain was placed, the fluid volume is reviewed and the drain is removed once output falls to the level the surgeon considers safe. A soft, fluid-filled swelling called a seroma is common after mastectomy or lymph node removal; most are left alone to reabsorb, and a few are drained with a needle if they are uncomfortable. Bruising fades over weeks. Numbness over the upper inner arm, caused by a small sensory nerve that runs through the surgical field, may be permanent and is worth knowing about in advance so it does not alarm you.

Shoulder movement is assessed early because stiffness sets in quickly. Gentle stretching exercises are typically taught soon after surgery, and the NHS advises continuing them as instructed to restore range of motion and reduce the risk of long-term arm problems.

The pathology report is the emotional center of this visit. It confirms the tumor size, whether the margins were clear, how many lymph nodes were involved, the tumor grade, and the receptor status: estrogen receptor, progesterone receptor, and HER2. Those three results decide almost everything that follows. Hormone receptor–positive disease steers toward endocrine therapy; HER2-positive disease toward targeted antibodies; a positive node or a large tumor toward radiation or chemotherapy. Ask for a copy. You will refer to it for years.

Emotionally, this is also when many people first hear the word survivorship. It can feel premature. It is not; the planning starts here.

Follow-up during and after radiation therapy

Radiation to the breast or chest wall is usually delivered daily over one to several weeks, and the radiation oncology team sees patients weekly during treatment to monitor the skin. The main concern in this phase is radiation dermatitis, meaning inflammation of the skin in the treated field. It typically begins as pinkness and dryness during the second or third week, may progress to peeling or occasional moist breakdown in the skin folds, and usually settles over the weeks after the final session. The team checks for infection in any broken areas and advises on skin care.

Fatigue is the other predictable companion. It tends to build gradually, peaks toward the end of the course, and can take several weeks to a few months to lift. Follow-up visits after radiation ask about energy for that reason, and mild aerobic activity such as walking is generally encouraged as tolerated.

The first post-radiation visit, often around a month after finishing, looks at how the skin has recovered and whether the breast feels firmer or looks different. Some firmness and a slightly smaller, higher breast are expected long-term effects. Later visits keep an eye on rarer late changes: rib tenderness, a dry cough that could suggest inflammation of the lung tissue beneath the treatment field, and, in people treated on the left side, heart health over the following years.

The first mammogram after radiation is usually scheduled about six to twelve months after the treated breast has settled, because scar tissue and swelling can make early images hard to read. That first film becomes the new baseline, and radiologists compare every later mammogram to it. Getting it done at the same center, or carrying the images with you, makes those comparisons more reliable.

During and after chemotherapy and HER2-targeted treatment

Chemotherapy comes with its own dense schedule of checks that runs in parallel with everything above. Before each cycle, a blood count confirms that white cells, red cells, and platelets have recovered enough to proceed. Kidney and liver function are checked for the same reason. These are the only routine blood tests most people will have, and they stop when chemotherapy stops.

Taxane-class drugs can damage the small nerves in the hands and feet, producing tingling or numbness known as peripheral neuropathy. Clinicians ask about it at every cycle because catching it early allows the plan to be adjusted; changes to treatment are the oncologist’s call, never something to attempt alone. The National Cancer Institute notes that neuropathy may improve over months after chemotherapy ends but can persist in some people, so follow-up visits keep asking about it well into the next year.

HER2-targeted antibodies, given to people whose tumors overproduce the HER2 protein, are usually continued for around a year after chemotherapy. Their most important monitored side effect is a fall in the heart’s pumping strength. An echocardiogram, an ultrasound of the heart, is performed before treatment and repeated at regular intervals during it, typically every few months, so that any drop can be detected while it is still reversible. Follow-up in this phase therefore includes a cardiology-style review of breathlessness, ankle swelling, and exercise tolerance.

Menstrual periods often stop during chemotherapy. Whether they return depends heavily on age, and this uncertainty affects which hormone therapy is chosen afterward, so expect the team to ask about periods for a long time. Hair, nails, and taste usually recover over the months after treatment, and the first follow-up visits after chemotherapy spend as much time on these recovering systems as on recurrence.

The hormone therapy years: what is monitored and for how long

For the roughly two-thirds of breast cancers that carry estrogen receptors, the longest phase of treatment is endocrine therapy, taken as a daily tablet for years. The National Cancer Institute describes courses of five to ten years, and the length is decided by the oncologist based on recurrence risk and how well the medicine is tolerated. Follow-up during this phase is largely about staying on it safely.

Two classes are used. Selective estrogen receptor modulators, of which tamoxifen is the generic example, sit in the estrogen receptor and block it in breast tissue. Aromatase inhibitors, used after menopause, shut down the enzyme that makes estrogen from other hormones in fat and muscle, lowering estrogen throughout the body. Each has a monitoring pattern shaped by its mechanism.

Because the first class acts like estrogen in the uterus, follow-up asks about any vaginal bleeding after menopause, which always warrants investigation. The same class slightly raises the chance of blood clots, so calf pain or sudden breathlessness is treated urgently. Routine uterine scans are not recommended in the absence of symptoms.

Because aromatase inhibitors remove estrogen’s protective effect on bone, a bone density scan, called a DXA, is typically obtained at the start and repeated periodically so that thinning can be treated before a fracture occurs. Joint stiffness, especially in the hands and on first waking, is common and is asked about at every visit, as are hot flashes, vaginal dryness, and mood.

The quiet purpose of these conversations is adherence. Studies summarized by Mayo Clinic and the National Cancer Institute show that many people stop early because of side effects, and stopping without discussion forfeits protection. If the tablet is making life miserable, say so at the visit. Options exist, and the decision about them belongs to the prescriber.

How often is a mammogram needed after breast cancer?

Once a year, for as long as there is breast tissue to image. That short answer is consistent across the NHS, which describes yearly mammograms for five years followed by routine screening, and across US oncology guidelines, which recommend annual mammography indefinitely for anyone with a remaining breast.

The first post-treatment mammogram is timed around six to twelve months after the end of radiation for the treated breast, and the untreated breast is imaged on its usual annual cycle. After a mastectomy without reconstruction there is no breast tissue to compress, so no mammogram of that side is performed; the chest wall is examined by hand instead. After reconstruction with an implant or the body’s own tissue, mammography of the reconstructed side is generally not routine either, though your surgeon may recommend other imaging in specific situations.

Why not add breast MRI for everyone? MRI is more sensitive than mammography but also picks up more findings that turn out to be harmless, leading to biopsies that would never have been needed. Guidelines therefore reserve it for people at especially high risk, such as those with inherited variants in genes like BRCA1 or BRCA2, or those whose breasts are very dense and hard to read on mammography. Whether you fall into one of those groups is a conversation to have with your team, not a decision to make from a search result.

Ultrasound is used to look at specific lumps or to guide a needle, not as a routine surveillance tool. Thermography, sometimes marketed as a gentler alternative, has no evidence to support it for detecting breast cancer and is not recommended by any major health body.

Bring your prior images if you change centers. A radiologist comparing today’s film to last year’s is doing the single most powerful thing in surveillance.

Tumor markers and body scans: why they are usually not part of follow-up

This surprises people more than anything else in survivorship care. Surely a blood test or a full-body scan every year would be safer than waiting for a symptom? The evidence says otherwise, and the reasoning is worth understanding rather than simply accepting.

Tumor markers are proteins such as CA 15-3 or CEA that some breast cancers shed into the blood. The problem is that they rise for many other reasons, including benign breast conditions, liver disease, and smoking, and they stay normal in a substantial share of people whose cancer has actually returned. Randomized trials conducted in the 1990s compared intensive follow-up, with regular blood tests, bone scans, and chest imaging, against standard clinical follow-up in people with no symptoms. Both groups lived equally long. The intensively monitored group simply learned about recurrence a little earlier, spent more time worrying about false alarms, and underwent more procedures. Guidelines from oncology societies in the United States and Europe have discouraged routine markers and scans in asymptomatic people ever since.

The same logic applies to CT, PET, and bone scans. They expose the body to radiation, find incidental spots that require further workup, and have not been shown to change outcomes when used as routine screening after breast cancer. They remain excellent tools when there is a reason: a new persistent pain, an unexplained cough, abnormal liver tests. In that setting, ordered to answer a specific question, they are exactly right.

Some oncologists do order markers in individual circumstances, particularly for people with metastatic disease where the trend can help track response to treatment. That is a different use with a different purpose. If your team has chosen not to order them, it is not neglect; it is the standard of care, backed by data.

Watching the arm: lymphedema surveillance after node surgery

Lymphedema is a chronic swelling of the arm, hand, breast, or chest wall caused by damage to the lymphatic drainage channels during lymph node surgery or radiation. The National Cancer Institute’s patient information notes that it can appear within days of treatment or many years later, and that once established it tends to be a lifelong condition to manage. Follow-up visits therefore keep an eye on the arm indefinitely.

The risk tracks with how much was done. Removal of one to a few sentinel nodes, the first nodes that drain the breast, carries a small risk. Removal of most of the axillary nodes, called an axillary dissection, carries a larger one, and radiation to the armpit adds to it. Higher body weight and infection in the arm raise the risk further.

At the visit, the clinician compares the two arms visually and may measure the circumference at several fixed points. Some centers use a device that passes a tiny electrical current through the arm to estimate fluid content, catching changes before they are visible. A difference detected early can be managed with a compression sleeve and specialist physical therapy, and small increases in swelling sometimes resolve completely with prompt attention.

People are usually asked to report a feeling of heaviness, tightness, or a ring or watch that suddenly fits differently, since these sensations often precede measurable swelling. Any redness, warmth, or fever in the affected arm is treated as a possible skin infection and needs same-day assessment, because infection both results from and worsens lymphedema.

Old advice to never lift anything heavy with the affected arm has softened. Supervised, gradually progressive strength training has been shown in randomized trials to be safe and may even reduce flare-ups. The key words are gradual and supervised; a lymphedema-trained therapist can set the starting point.

Who follows the standard schedule, and who is asked for something different

The tapering three-to-six-month pattern is built for people treated for early-stage invasive breast cancer with the intention of removing all detectable disease. Several groups sit outside that template, and their schedules look different for good reasons.

People living with metastatic breast cancer, meaning cancer that has spread to distant organs, are not in surveillance at all; they are in ongoing treatment. Their visits happen on the rhythm of that treatment, with scans and blood tests chosen to track how the cancer is responding. The word follow-up is used loosely here, but the goals are different.

People treated for ductal carcinoma in situ, a non-invasive change confined to the milk ducts, usually have a lighter version of the schedule: an annual mammogram and periodic exams, often moving to primary care sooner, because the risk of distant recurrence is very low.

People with an inherited variant in a high-risk gene, or with a strong family history, are often asked to do more rather than less: annual breast MRI alternating with mammography, discussion of risk-reducing surgery, and screening for other cancers linked to the same gene. Genetic counseling is part of their follow-up, and relatives may be invited for testing.

People who had immediate reconstruction have an extra thread of surgical follow-up for implants or tissue flaps, sometimes for years, including checks for capsular contracture, meaning tightening of scar tissue around an implant.

Finally, some people are asked to wait before certain steps. Reconstruction may be deferred until after radiation. A first mammogram may be pushed back until swelling settles. Starting hormone therapy may be delayed until the ovaries recover or until periods clearly stop. Waiting here is not indecision; it is sequencing, and the team should be able to explain each pause.

Breast cancer surveillance guidelines beyond five years

Five years used to feel like a finish line. It is better understood as a milestone. For hormone receptor–positive tumors in particular, recurrence risk does not vanish at year five but continues at a low, steady rate for well over a decade, which is why longer courses of endocrine therapy are sometimes recommended and why annual mammography continues for life. Hormone receptor–negative and HER2-positive tumors carry more of their risk in the first few years and less later on. Your oncologist can tell you which pattern your tumor fits.

Surveillance guidelines from oncology societies allow, and often encourage, transfer of follow-up to a primary care clinician after a few years, provided that clinician receives a clear written summary. The National Cancer Institute calls this a survivorship care plan: a document listing the diagnosis, every treatment received with dates, the known late effects to watch for, the schedule of recommended tests, and who to contact if something arises. Ask for one before you leave specialist care. It turns an anxious handover into a shared checklist.

Late effects that a primary care clinician watches for include heart disease after certain chemotherapy classes or left-sided radiation, osteoporosis after aromatase inhibitors or early menopause, and, rarely, second cancers related to treatment. Ordinary screening does not stop: colon cancer screening, cervical screening if applicable, blood pressure, cholesterol, and vaccinations all continue.

The annual mammogram remains the one cancer-specific test. Many people find that the week before it brings back the old fear in full force, even fifteen years on. That reaction is normal and widely reported; it does not mean anything about the result.

Discharge from oncology clinic, when it comes, should include a clear route back in. Most centers keep a rapid-access line for former patients with new concerns. Know the number before you need it.

Bones, heart, hormones and mood: the whole-person checks

A good follow-up visit spends surprisingly little time on cancer. Once the exam is done and the mammogram is booked, the conversation turns to the systems that treatment has quietly affected.

Bone comes first for many. Early menopause from chemotherapy, ovarian suppression, and aromatase inhibitors all accelerate bone loss. Follow-up includes periodic bone density scans for those at risk, a check that calcium and vitamin D intake are adequate, and encouragement toward weight-bearing exercise. If the scan shows thinning, medicines that slow bone breakdown may be discussed; whether and when to use them is the prescriber’s decision.

Heart health is the second theme, and it grows more important with each passing year. Anthracycline-class chemotherapy, HER2-targeted antibodies, and radiation to the left chest can each leave the heart slightly more vulnerable, and the ordinary risks of blood pressure, cholesterol, weight, and smoking still apply. Follow-up visits therefore check blood pressure and ask about exercise tolerance, and some people are referred for a cardiology review.

Menopausal symptoms, whether natural or treatment-induced, deserve their own airtime. Hot flashes, night sweats, sleep disruption, vaginal dryness, and pain with intercourse are common, under-reported, and manageable. Standard hormone replacement is generally avoided after hormone-sensitive breast cancer, but non-hormonal approaches exist and a clinician can explain them.

Fertility questions arise for younger patients and should be raised early rather than late. Weight, alcohol, and physical activity all have evidence linking them to recurrence risk, and follow-up is a natural place to set realistic goals.

Fear of recurrence, low mood, and difficulty concentrating, sometimes called chemo brain, are as real as any physical late effect. Clinics increasingly screen for distress at each visit. Saying yes to a referral for psychological support is not weakness; it is part of the schedule working as intended.

What people often get wrong about follow-up after breast cancer

“If they aren’t scanning me, they aren’t looking hard enough.” The opposite is closer to the truth. Routine scans in people without symptoms have been tested in randomized trials and did not help people live longer, while generating false alarms and radiation exposure. A careful exam plus an annual mammogram is the evidence-based standard, not a budget version of care.

“A normal follow-up visit means I am cancer-free.” A normal exam and mammogram mean nothing detectable was found that day. Clinicians choose their words carefully for this reason, and the right response to a good visit is relief, not a guarantee.

“Five years and I’m done.” For hormone-sensitive tumors, a meaningful share of recurrences happen after year five, which is precisely why endocrine therapy sometimes continues to ten years and mammography continues for life.

“I can quietly stop the hormone tablets; the cancer is gone anyway.” The tablets are the treatment for the microscopic disease that no scan can see. Stopping early is common and forfeits protection. If side effects are intolerable, that is a conversation to have with the prescriber, who has options.

“I must never lift anything with that arm again.” Gradual, supervised strength training is safe for most people at risk of lymphedema and may reduce flares. Sudden heavy exertion and skin injury are the things to avoid.

“Any new ache means it has come back.” Most aches in the years after treatment are musculoskeletal, especially on aromatase inhibitors. The distinguishing features of bone recurrence are persistence, worsening at night, and lack of relation to movement, and the rule is simple: anything lasting more than two weeks gets reported, and the team decides whether to image it.

“Follow-up is only about the cancer.” Heart, bone, mood, and sexual health are part of the appointment. Bringing them up is using the visit properly.

Questions to ask your care team about your follow-up plan

Follow-up visits are short, and the most useful ones are the ones you arrive at with a list. These questions cover the ground most people wish they had asked earlier.

• How often will I be seen over the next year, and who will I see: surgeon, medical oncologist, radiation oncologist, nurse specialist, or a combination?
• When is my first post-treatment mammogram, which breast or breasts will be imaged, and where should I have it done so that images can be compared year to year?
• Based on my tumor’s receptor status and stage, when is my risk of recurrence highest, and how does that shape my schedule?
• Am I in a group that needs breast MRI or genetic counseling?
• Will I have bone density scans or heart scans, and how often?
• Which side effects of my hormone therapy should I report straight away, and which can wait for the next visit?
• How long is my endocrine therapy planned to last, and what would prompt you to extend or shorten it?
• What is my personal risk of lymphedema, and should I see a lymphedema therapist now, before any swelling appears?
• What symptoms between visits should make me call, and what number do I call, including evenings and weekends?
• When will I receive a written survivorship care plan, and who will hold my follow-up once I leave the oncology clinic?
• Are there exercise, weight, or alcohol targets you would like me to work toward, and can you refer me to support for them?
• Who can I talk to about mood, fear of recurrence, sleep, or sexual health?

Bring a notebook or ask permission to record the answers. Many clinics will also copy letters to you; ask for that as a default. The point is not to interrogate the team but to leave each visit knowing what happens next and why.

When to call your doctor between follow-up visits

The scheduled visits are a safety net, not a fence. The single most important rule of survivorship care is that new, persistent, or unexplained symptoms are reported when they appear, not saved for the next appointment. Guidelines from the NHS and the National Cancer Institute both stress that most recurrences are found because a patient noticed something between visits and picked up the phone.

Call your oncology team promptly, without waiting for a scheduled date, if you notice any of the following:

• A new lump or thickening in either breast, the mastectomy scar, the chest wall, the armpit, or above the collarbone.
• Skin changes on the breast or chest wall: redness, dimpling, a rash that does not settle, or a nipple that has begun to turn inward or discharge.
• Bone pain that persists for more than two weeks, is worse at night, or is not linked to movement or injury.
• A cough or breathlessness lasting more than a few weeks, or any coughing up of blood.
• Persistent headaches, new visual changes, unsteadiness, or weakness or numbness in a limb.
• Loss of appetite, unexplained weight loss, jaundice, or abdominal swelling.
• Swelling, heaviness, or tightness in the arm or hand on the treated side, especially with redness, warmth, or fever, which may indicate infection.
• Any vaginal bleeding after menopause while on hormone therapy.

Seek emergency care the same day for sudden chest pain, sudden breathlessness, a swollen painful calf, a fever with shaking chills during or soon after chemotherapy, or sudden confusion or weakness on one side of the body. These can signal a blood clot, a serious infection, or a stroke and cannot wait.

Most calls will turn out to be nothing. Your team would far rather hear from you ten times about a benign muscle strain than miss the one call that mattered. Every judgment about what to investigate, and how, rests with the clinicians who know your history.

Frequently asked questions

How often do you need a mammogram after breast cancer?

Once a year, for as long as you have breast tissue to image. The NHS describes annual mammograms for five years after treatment before returning to routine screening, and US oncology guidelines recommend yearly mammography indefinitely. After a mastectomy without reconstruction, that side is examined by hand rather than imaged. Your team may add breast MRI if you carry a high-risk gene variant or have very dense breasts.

What happens at a breast cancer follow up appointment?

A nurse records your weight and blood pressure and asks about new symptoms. The clinician examines the treated breast or scar, the other breast, the armpit and collarbone area, and compares your arms for swelling. You discuss side effects of any hormone therapy, bone and heart health, mood, and sexual health. An annual mammogram is arranged, and other tests are ordered only for a specific reason.

Are tumor markers checked after breast cancer treatment?

Not routinely. Blood tumor markers such as CA 15-3 and CEA rise for many non-cancer reasons and stay normal in many actual recurrences, and randomized trials showed that intensive monitoring with markers and scans did not help people without symptoms live longer. Guidelines therefore recommend against them for routine surveillance. They are sometimes used in metastatic disease to track response to treatment, which is a different purpose.

Do breast cancer surveillance guidelines include CT or PET scans?

No, not for people without symptoms. Body scans expose you to radiation, frequently find harmless spots that need further workup, and have not been shown to improve outcomes when used as routine screening after early breast cancer. They are ordered when a specific symptom needs an answer, such as persistent bone pain or a lingering cough. In that situation they are exactly the right tool.

How long does follow-up with an oncologist last after breast cancer?

Often around five years, though this varies by center and by tumor type. Many people are then transferred to a primary care clinician with a written survivorship care plan, while annual mammograms continue for life. People with hormone receptor–positive tumors on extended endocrine therapy, or with inherited gene variants, may stay under specialist review longer. Your team will tell you what applies to you.

Why do follow-up visits get less frequent over time?

Because recurrence risk for many tumor types is highest in the first two to three years and falls afterward, and because the early visits also carry the workload of healing, side effects, and starting hormone therapy. Spacing visits more widely as time passes matches the schedule to the risk. Hormone receptor–positive tumors keep a low but steady risk for many years, which is why some monitoring never fully stops.

What is checked for lymphedema at follow-up visits?

The clinician compares both arms visually and may measure circumference at fixed points or use a device that estimates fluid content through a tiny electrical current. You will be asked about heaviness, tightness, or jewelry fitting differently, since these often come before visible swelling. Early changes can be managed with compression and specialist therapy, and any redness, warmth, or fever in the arm is assessed the same day.

Will I have bone density scans during breast cancer follow-up?

Possibly, depending on your treatment. Aromatase inhibitors, ovarian suppression, and chemotherapy-induced early menopause all speed bone loss, so a DXA bone density scan is typically obtained at the start of such treatment and repeated periodically. If thinning is found, medicines that slow bone breakdown may be discussed. The timing and any prescribing decisions are made by your treating clinician.

Is it normal to feel anxious before every follow-up appointment?

Yes, and it is widely reported even many years after treatment. The days before a mammogram or clinic visit often bring back the fear from diagnosis, and this reaction does not predict the result. Many clinics now screen for distress at each visit and can refer you to psychological support, survivorship groups, or a nurse specialist. Mentioning the anxiety is a legitimate use of the appointment.

What symptoms should make me call before my next scheduled visit?

Any new lump or skin change in the breast, scar, chest wall, armpit or collarbone area; bone pain lasting more than two weeks, especially at night; a cough or breathlessness for more than a few weeks; persistent headaches or new weakness; unexplained weight loss; arm swelling with redness or fever; or vaginal bleeding after menopause on hormone therapy. Sudden chest pain, a swollen calf, or fever during chemotherapy need same-day emergency care.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.